Chemomab Therapeutics (CMMB) Short-term Investments (2020 - 2025)

Chemomab Therapeutics (CMMB) has 6 years of Short-term Investments data on file, last reported at $2.8 million in Q4 2025.

• Quarterly Short-term Investments fell 65.81% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (down 65.81% YoY) and the FY2025 annual result came in at $2.8 million, down 65.81% from the prior year.
• Short-term Investments eased to $2.8 million in Q4 2025, from $3.1 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $46.0 million in Q4 2021 to a low of $23000.0 in Q1 2021.
• A 5-year average of $17.2 million and a median of $12.1 million in 2023 frame the typical range for Short-term Investments.
• The widest YoY moves for Short-term Investments: up 191462.5% in 2021, down 81.75% in 2021.
• Tracing CMMB's Short-term Investments over 5 years: stood at $46.0 million in 2021, then tumbled by 42.63% to $26.4 million in 2022, then plunged by 60.22% to $10.5 million in 2023, then retreated by 21.89% to $8.2 million in 2024, then tumbled by 65.81% to $2.8 million in 2025.
• The last three Short-term Investments figures came in at $2.8 million (Q4 2025), $3.1 million (Q3 2025), and $3.9 million (Q2 2025), per Business Quant data.